Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Co., Ltd. is a Japan-based pharmaceutical company specializing in the research, development, and commercialization of innovative medicines. Formed in 2005 through the merger of Daiichi Pharmaceutical and Sankyo, the company focuses primarily on oncology, cardiovascular diseases, and rare diseases. Its portfolio includes therapies such as Trastuzumab deruxtecan for HER2-positive cancers, Edoxaban for blood clotting disorders, and groundbreaking antibody-drug conjugates like Anti-HER3-ADC. With a market capitalization of approximately $48 billion, Daiichi Sankyo operates globally, delivering treatments that address unmet medical needs. The company’s emphasis on precision medicine and targeted therapies has positioned it as a key player in advancing cancer care, supported by strategic collaborations and a pipeline emphasizing next-generation biopharmaceuticals. Headquartered in Tokyo, its work significantly impacts global healthcare systems through cutting-edge drug development and therapeutic innovation.